// App-Quantinova.ai

S128 : A RANDOMISED COMPARISON OF CPX-351 AND FLAG-IDA IN HIGH RISK ACUTE MYELOID LEUKAEMIA. RESULTS FROM THE NCRI AML19 TRIAL

Researchers

Presenter

  • Nigel Russell

Principal Investigators

  • Charlotte Wilhelm-Benartzi

  • Steve Knapper

  • Leona Batten

  • Joanna Canham

  • Emily Hinson

  • Ulrik Malthe Overgaard

  • Jad Othman

  • Richard Dillon

  • Priyanka Mehta

  • Panos Kottaridis

  • Jamie Cavenagh

  • Claire Hemmaway

  • Claire Arnold

  • Mike Dennis

Medical Centers

  • Department of Haematology,St Bartholomew's Hospital,London,Reino Unido

  • Aukland Hospital,Aukland,Nouvelle-zélande

  • School of Medicine, Cardiff University, Cardiff, United Kingdom

  • Belfast City Hospital, Belfast, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust, Department of Haematology,London,Regno Unito

  • Department of Histopathology, St. Bartholomews Hospital, London, United Kingdom

  • Copenhagen University Hospital, Copenhagen, Denmark

  • Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom

  • School of Medicine, Cardiff University, Cardiff, United Kingdom

  • University Hospitals of Bristol and Weston NHS Trust,Bristol,Royaume-uni

  • Copenhagen University Hospital,Copenha

  • Belfast City Hospital,Belfast,Regno Unito

  • Department of Haematology,St Bartholomew's Hospital,London,Reino Unido

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • Auckland City Hospital,Auckland,新西兰

  • Belfast City Hospital,Belfast,Regno Unito

  • Centre for Trials Research, Cardiff University,Cardiff,Verenigd Koninkrijk

  • School of Medicine,Cardiff Uni

  • Copenhagen University Hospital, Copenhagen, Denmark

  • The Christie NHS Foundation Trust. On behalf of the NCRI AML Working Group,Manchester,Regno Unito

  • Aukland Hospital,Aukland,Nouvelle-zélande

  • Department of Medical and Molecular Genetics,K

  • Belfast City Hospital, Belfast, Ireland

  • The Christie NHS Foundation Trust. On behalf of the NCRI AML Working Group,Manchester,Regno Unito

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Department of Haematology,St Bartholomew's Hospital,London,Reino Unido

  • Belfast City Hospital,Belfast,Vereinigtes Königreich

  • School of Medicine,Cardiff University,Cardiff,Verenigd Koninkrijk

  • The Christie NHS Foundation Trust. On behalf of the NCRI AML Working Group,Manchester,Regno Unito

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • Medical and Molecular Genetics, Kings College, London, London, United Kingdom

  • University College London Hospitals NHS Foundation Trust,London,Vereinigtes Königreich

  • Department of Haematology,St Bartholomew's Hospital,London,Vereinigtes Königreich

  • Aukland Hospital,Aukland,Nouvelle-zélande

  • Aukland Hospital,Aukland,Nouvelle-zélande

  • Aukland Hospital,Aukland,Новая Зеландия

  • University Hospitals of Bristol and Weston NHS Trust,Bristol,Royaume-uni

  • Aukland Hospital,Aukland,Nouvelle-zélande

  • School of Medicine, Cardiff University, Cardiff, United Kingdom

  • Department of Medical and Molecular Genetics,Kings College London,London,Royaume-uni

  • Aukland Hospital,Aukland,Nouvelle-zélande

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • School of Medicine,Cardiff University,Cardiff,Verenigd Koninkrijk

  • Univer

  • Department of Medical and Molecular Genetics,Kings College London,London,Vereinigtes Königreich

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • Medical and Molecular Genetics, Kings College, London, London, United Kingdom

  • University Hospitals of Bristol and Weston NHS Trust,Bristol,Royaume-uni

  • Belfast City Hospital,Belfast,Verenigd Koninkrijk

  • University Hospitals of Bristol and Weston NHS Trust,Bristol,Royaume-uni

  • Belfast City Hospital,Belfast,Соединённое Королевство

  • Guy's and St Thomas' NHS Foundatio

  • School of Medicine, Cardiff University, Cardiff

  • Department of Hematology,

  • Belfast City Hospital,Belfast,Royaume-uni

  • Copenhagen University Hospital, Copenhagen, Denmark

  • Centre for Trials Research, Cardiff University,Cardiff,Royaume-uni

  • Aukland Hospital,Aukland,Nouvelle-zélande

  • Guy's and St Thomas' NHS Foundation Trust, Department of Haematology,London,Regno Unito

  • Copenhagen University Hospital, Copenhagen, Denmark

  • Copenhagen University Hospital, Copenhagen, Denmark

  • Guy's and St Thomas' NHS Foundation Trust, Department of Haematology,London,Regno Unito

  • University Hospital Wales

  • The Christie NHS Foundation Trust. On behalf of the NCRI AML Working Group,Manchester,Regno Unito

Locations

  • United Kingdom

  • Denmark

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Nucleophosmin 1

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • daunorubicin + cytarabine

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • ISRCTN78449203

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved